What biomarker tests are recommended for Lung Cancer

Biomarker Testing for Lung Cancer

Biomarker testing is a crucial part of lung cancer care because it identifies specific genetic changes in your cancer cells that determine which treatments will work best for you. Think of biomarkers as a "fingerprint" of your cancer—what helps one person might not help another.

Why Biomarker Testing Matters

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, biomarker tests help your doctors:

• Determine if you're eligible for targeted therapies (drugs designed to attack specific mutations)
• Decide if immunotherapy is appropriate for you
• Choose the most effective treatment plan
• Understand your cancer's behavior

Which Biomarkers Should Be Tested?

The NCCN Guidelines recommend broad molecular profiling for most lung cancer patients. This means testing for multiple biomarkers at once, rather than testing one at a time. Here are the key biomarkers your care team should evaluate:

Driver Mutations (genetic changes that fuel cancer growth)

These are found in about 1 in 3 people with metastatic adenocarcinoma lung cancer:

• EGFR mutations (exon 19 deletion, L858R, and other variants) — very common
• ALK rearrangement — a gene fusion that responds well to targeted drugs
• ROS1 rearrangement — another gene fusion with targeted treatment options
• BRAF V600E mutation — found in some lung cancers
• KRAS G12C mutation — increasingly important as new treatments become available
• MET exon 14 skipping — a specific mutation pattern
• RET rearrangement — a gene fusion
• NTRK gene fusion — a rare but actionable mutation
• ERBB2 (HER2) mutations — similar to breast cancer biomarkers

Immune Biomarker

• PD-L1 protein level — This protein on cancer cells helps them hide from your immune system. All lung cancers should be tested for PD-L1 because it determines eligibility for immunotherapy drugs.

How Testing Is Done

According to the NCCN Guidelines, biomarker testing can be performed using:

• Tissue samples from a biopsy or surgery (preferred method)
• Blood tests (plasma testing) — if tissue isn't available or there isn't enough tissue
• Next-generation sequencing (NGS) — a method that can test many genes at once
• Immunohistochemistry (IHC) — specifically for detecting PD-L1

Important Timeline

Broad molecular profiling can take up to 3 weeks to complete because multiple genes are being analyzed. This is normal and worth the wait, as the results directly guide your treatment decisions.

What If There's Not Enough Tissue?

If your initial biopsy doesn't provide enough tissue for testing, your care team may:

• Schedule a second biopsy
• Use a blood sample to test for biomarkers in your plasma (circulating tumor DNA)
• Discuss alternative approaches with you

What If No Biomarkers Are Found?

Some lung cancers don't have known biomarkers with available treatments. In these cases, treatment decisions are based on:

• Your lung cancer cell type (adenocarcinoma, squamous cell, etc.)
• PD-L1 level
• Other clinical factors your team evaluates

Questions to Ask Your Care Team

1. Have all the recommended biomarkers been tested on my cancer? (Make sure broad molecular profiling was done, not just one or two tests)
2. When will my biomarker results be available?
3. What do my specific results mean for my treatment options?
4. If no driver mutations were found, what does that mean for my treatment plan?
5. Can I get a copy of my complete biomarker test results to keep in my records?

Key Takeaway

According to the NCCN Guidelines, biomarker testing is essential for most lung cancer patients because it opens doors to personalized treatment options. Don't hesitate to ask your care team about which biomarkers have been tested and what the results mean for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.